CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA
Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.